Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: The addition study

Urology

Volumn 82, Issue 4, 2013, Pages 887-893

  Takeda, Masayuki ^a   Nishizawa, Osamu ^b   Gotoh, Momokazu ^c   Yoshida, Masaki ^d   Takahashi, Satoru ^e   Masumori, Naoya ^f  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^e NIHON UNIVERSITY   (Japan)

^f SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAFENACIN; TAMSULOSIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DAYTIME; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MICTURITION DISORDER; MONOTHERAPY; MULTICENTER STUDY; NIGHT; NOCTURIA; OPEN STUDY; OVERACTIVE BLADDER; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP QUALITY; TIME; TREATMENT DURATION; TREATMENT FAILURE; URGE INCONTINENCE; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; URINE VOLUME; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; SULFONAMIDES; URINARY BLADDER, OVERACTIVE;

EID: 84884979114     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.05.008     Document Type: Article

References (28)

1. J.L. Bosch, W.C. Hop, W.J. Kirkels, and F.H. Schröder Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community Urology 46 3 Suppl A 1995 34 40
2. P. Boyle, C. Robertson, and C. Mazzetta The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study BJU Int 92 2003 409 414
3. G. Welch, K. Weinger, and M.J. Barry Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study Urology 59 2002 245 250
4. P. Boyle, C. Robertson, and C. Mazzetta The relationship between lower urinary tract symptoms and health status: the UREPIK study BJU Int 92 2003 575 580
5. G. Engström, L. Henningsohn, G. Steineck, and J. Leppert Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract BJU Int 95 2005 810 815
6. W.P. Witjes, J.J. de la Rosette, and J.L. Donovan The International Continence Society "Benign Prostatic Hyperplasia" Study: international differences in lower urinary tract symptoms and related bother J Urol 157 1997 1295 1300
7. K. Kawabe [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia] Yakugaku Zasshi 126 Spec No. 2006 199 206 [in Japanese]
8. P. Narayan, C.P. Evans, and T. Moon Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia J Urol 170 2 Pt 1 2003 498 502
9. H. Lepor Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group Urology 51 1998 892 900
10. P. Abrams, C.C. Schulman, and S. Vaage Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). The European Tamsulosin Study Group Br J Urol 76 1995 325 336
11. O. Yamaguchi, H. Kakizaki, and Y. Homma Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study Urology 78 2011 126 133
12. S.A. Kaplan, K. McCammon, and R. Fincher Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency J Urol 182 2009 2825 2830
13. S.A. Kaplan, C.G. Roehrborn, and E.S. Rovner Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JAMA 296 2006 2319 2328
14. C. Chapple, S. Herschorn, and P. Abrams Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers Eur Urol 56 2009 534 541
15. O. Nishizawa, O. Yamaguchi, and M. Takeda Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics Low Urin Tract Symptoms 3 2011 29 35
16. S.J. Jacobsen, D.J. Jacobson, and C.J. Girman Natural history of prostatism: risk factors for acute urinary retention J Urol 158 1997 481 487
17. K. Thomas, G. Oades, C. Taylor-Hay, and RS Kirby Acute urinary retention: what is the impact on patients' quality of life? BJU Int 95 2005 72 76
18. Takeda M, Takahashi S, Nishizawa O, et al. Imidafenacin, a novel anticholinergic, significantly improves both nocturia and sleep disorders in OAB patients. EPOCH (evaluation of anticholergics in patients with overactive bladder and nocturia for cared-health) study in Japan. Available at: http://www.ics.org/Abstracts/Publish/47/000321.pdf. Abstract #321. Accessed May 30, 2013.
19. M. Takeda, S. Takahashi, and O. Nishizawa [Imidafenacin, a novel anticholinergic, significantly improves nocturia, sleep disorders and quality of life in OAB patients-EVOLUTION study] Jpn J Urol Surg 23 2010 1443 1452 [in Japanese]
20. Y. Homma, M. Yoshida, and N. Seki Symptom assessment tool for overactive bladder syndrome - overactive bladder symptom score Urology 68 2006 318 323
21. O. Yamaguchi, O. Nishizawa, and M. Takeda Clinical guidelines for overactive bladder Int J Urol 16 2009 126 142
22. M.J. Barry, F.J. Fowler Jr., and M.P. O'Leary Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association Med Care 33 4 Suppl 1995 AS145 AS155
23. Kakizaki H, Wada N, Numata A. Comparison of tamsulosin with or without solifenacin in men with benign prostatic hyperplasia and overactive bladder: short-term results on efficacy and safety. Available at: http://www.ics.org/ Abstracts/Publish/46/000287.pdf. Abstract #287. Accessed May 30, 2013.
24. M. Matsushita Evaluation of imidafenacin in benign prostatic hyperplasia patients with nocturia Prog Med 28 2008 2961 2963 [in Japanese]
25. M. Gotoh, Y. Homma, O. Yokoyama, and O. Nishizawa Responsiveness and minimal clinically important change in overactive bladder symptom score Urology 78 2011 768 773
26. F. Montorsi, T. Henkel, and A. Geboers Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study Int J Clin Pract 64 2010 1042 1051
27. O. Yamaguchi Antimuscarinics and overactive bladder: other mechanism of action Neurourol Urodyn 29 2010 112 115
28. T. Yamazaki, Y. Muraki, and T. Anraku In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats Naunyn Schmiedebergs Arch Pharmacol 384 2011 319 329